Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation.

NCT00192608 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT00192608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00192608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation.
Lead sponsor
Kirby Institute
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2004
Completion date
May 31, 2006
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections